



Please type a plus sign (+) inside this box → ☒

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(To be used for all correspondence after initial filing)

Application Number	09/648,816
Filing Date	08/25/00
First Named Inventor	Michael R. Yeaman
Group Art Unit	1354
Examiner Name	
Attorney Docket No.	660081.415C1

TECH CENTER 1600/2900

SEP 17 2001



RECEIVED

ENCLOSURES (check all that apply)


<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement; Form PTO-1449 <input type="checkbox"/> Cited References <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts under 37 C.F.R. 1.52 or 1.53 <input type="checkbox"/> Response to Missing Parts/Incomplete Application	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input checked="" type="checkbox"/> Request for Corrected Filing Receipt <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address <input type="checkbox"/> Declaration <input type="checkbox"/> Statement under 37 CFR 3.73(b) <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request for Refund	<input type="checkbox"/> CD(s), Number of CD(s) _____ <input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Return Receipt Postcard <input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below): <u>Copy of Updated Filing Receipt (corrected)</u> _____ _____ _____ _____
---	--	---

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Individual Name	Jeffrey C. Pepe, Ph.D.	 00500 PATENT TRADEMARK OFFICE
Signature		
Date	6/5/01	

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date specified below.		
Typed or printed name	Linda M. Povinelli	
Signature		Date: June 5, 2001



PATENT

I hereby certify that on the date specified below, this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to the Commissioner for Patents, Office of Initial Patent Examination, Customer Service Center, Washington, DC 20231.

June 5, 2001

Date

Linda M. Povinelli

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

SEP 17 2001

TECH CENTER 1600/2900

Applicants : Michael R. Yeaman *et al.*

Application No. : 09/648,816

Filed : August 25, 2000

For : *ANTIMICROBIAL PEPTIDES AND DERIVED METAPEPTIDES*

Art Unit : 1354

Docket No. : 660081.415C1

Date : June 5, 2001

Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231

REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents:

Attached is a copy of the official Filing Receipt received from the PTO in the above-identified application, for which issuance of a corrected Filing Receipt is respectfully requested. Please correct the following errors.

In Applicant(s) data, please correct the first inventor's name, which should read MICHAEL R. YEAMAN.

In Continuing Data as Claimed by Applicant data, please insert the following:

APPLN IS A CIP OF 09/622,561 08/18/00

WHICH IS A NATIONAL STAGE OF PCT/US99/03350 02/17/99

WHICH CLAIMS PRIORITY TO 09/025,319 02/18/98 ABN

The corrections to be made have also been marked in red on the copy of the enclosed filing receipt.

The corrections are not due to any error by applicants and no fee is due.



Respectfully submitted,

Seed Intellectual Property Law Group PLLC

A handwritten signature in cursive script, appearing to read "Jeffrey C. Pepe", is written over a horizontal line.

Jeffrey C. Pepe, Ph.D.

Registration No. 46,985

JCP:Imp

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

183082



KAM 10D14

UNITED STATES PATENT AND TRADEMARK OFFICE

1653

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov



Bib Data Sheet

FILE COPY

CONFIRMATION NO. 6324

SERIAL NUMBER 09/648,816	FILING DATE 08/25/2000 RULE	CLASS XXX	GROUP ART UNIT 2899	ATTORNEY DOCKET NO. 660081.415C1
APPLICANTS Michael R. Yeaman, Torrance, CA; Alexander J. Shen, Torrance, CA;				
** CONTINUING DATA ***** THIS APPLICATION IS A CIP OF 09/622,561 10/06/2000 WHICH IS A 371 OF PCT/US99/03350 02/17/1999 WHICH IS A CIP OF 09/025,319 02/18/1998 ABN				
** FOREIGN APPLICATIONS *****				
IF REQUIRED, FOREIGN FILING LICENSE GRANTED ** 10/06/2000				
** SMALL ENTITY **				
Foreign Priority claimed <input type="checkbox"/> yes <input type="checkbox"/> no 35 USC 119 (a-d) conditions met <input type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> Met after Allowance Verified and Acknowledged Examiner's Signature _____ Initials _____	STATE OR COUNTRY CA	SHEETS DRAWING 25	TOTAL CLAIMS 66	INDEPENDENT CLAIMS 16
ADDRESS David D McMasters Seed Intellectual Property Law Group PLLC 701 Fifth Avenue Suite 6300 Seattle, WA 98104-7092				
TITLE Antimicrobial peptides and derived metapeptides				
FILING FEE RECEIVED 1354	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:			
				<input type="checkbox"/> All Fees
				<input type="checkbox"/> 1.16 Fees (Filing)
				<input type="checkbox"/> 1.17 Fees (Processing Ext. of time)
				<input type="checkbox"/> 1.18 Fees (Issue)
				<input type="checkbox"/> Other _____
				<input type="checkbox"/> Credit



RECEIVED

FEB 05 2001

JCP

SEED INTELLECTUAL PROPERTY
LAW GROUP PLLCCOMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/648,816	08/25/2000	1653	1354	660081.415C1	25	66	16

David D McMasters
Seed Intellectual Property Law Group PLLC
701 Fifth Avenue
Suite 6300
Seattle, WA 98104-7092

FILING RECEIPT



0000000005721592

RECEIVED

SEP 17 2001

TECH CENTER 1600/2900

Date Mailed: 01/31/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Michael R. Yeaman, Torrance, CA ;
Alexander J. Shen, Torrance, CA ;

YEAMAN

Continuing Data as Claimed by Applicant

Application is a CIP of 09/622,561 filed 08/18/00
which is a 371 conversion of PCT/US99/03350 filed
02/17/99

Foreign Applications

which claims priority to 09/025,319 filed 02/18/98

If Required, Foreign Filing License Granted 10/06/2000

ABN

** SMALL ENTITY **

Title

Antimicrobial peptides and derived metapeptides

Preliminary Class

514

Data entry by : MASON, JAMES

Team : OIPE

Date: 01/31/2001





**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

RECEIVED

SEP 17 2001

TECH CENTER 1600/2900

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15 (b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231